{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:07:21Z","timestamp":1762542441431},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/pat.0000000000000293","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T21:30:57Z","timestamp":1436650257000},"page":"570-574","source":"Crossref","is-referenced-by-count":11,"title":["A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system"],"prefix":"10.1016","volume":"47","author":[{"given":"Anoop","family":"Enjeti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Granter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Rowlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/PAT.0000000000000293_bib0005","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","volume":"2007","author":"Branford","year":"2007","journal-title":"Haematology Am Soc Haematol Educ Program"},{"key":"10.1097\/PAT.0000000000000293_bib0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?","volume":"96","author":"Cayuela","year":"2011","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0000000000000293_bib0015","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0000000000000293_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1097\/PAT.0000000000000293_bib0030","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0035","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0000000000000293_bib0040","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0000000000000293_bib0045","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2014-06-578617","article-title":"Molecular response in CML: where is the bar?","volume":"124","author":"Baccarani","year":"2014","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","article-title":"Evaluation of the Cepheid GeneXpert BCR-ABL assay","volume":"9","author":"Jobbagy","year":"2007","journal-title":"J Mol Dis"},{"key":"10.1097\/PAT.0000000000000293_bib0065","doi-asserted-by":"crossref","unstructured":"O\u2019Dwyer ME, Swords R, Giles F, et al. Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). ASH Annual Meeting Abstracts 2011; cited 20 Oct 2014. https:\/\/ash.confex.com\/ash\/2011\/webprogram\/Paper41071.html","DOI":"10.1182\/blood.V118.21.3774.3774"},{"key":"10.1097\/PAT.0000000000000293_bib0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.leukres.2013.11.016","article-title":"Nilotinib 300mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response","volume":"38","author":"O\u2019Dwyer","year":"2014","journal-title":"Leuk Res"},{"key":"10.1097\/PAT.0000000000000293_bib0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1097\/PAT.0000000000000293_bib0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0000000000000293_bib0085","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/leu.2008.330","article-title":"Reply to \u2019What do we mean by sensitivity when we talk about detecting minimal residual disease?\u2019 by Steinbach and Debatin","volume":"23","author":"Ross","year":"2009","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0000000000000293_bib0090","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2019real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0000000000000293_bib0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","article-title":"Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era","volume":"12","author":"Goldman","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"10.1097\/PAT.0000000000000293_bib0100","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","author":"White","year":"2013","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0000000000000293_bib0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/PAT.0b013e32834e4203","article-title":"Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay","volume":"44","author":"McNiven","year":"2012","journal-title":"Pathology"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516300587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516300587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T22:54:57Z","timestamp":1599260097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302516300587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0031302516300587"],"URL":"https:\/\/doi.org\/10.1097\/pat.0000000000000293","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}